Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3

Aberrant NF-κB activity drives oncogenesis and cell survival in multiple myeloma (MM) and many other cancers. However, despite an aggressive effort by the pharmaceutical industry over the past 30 years, no specific IκBα kinase (IKK)β/NF-κB inhibitor has been clinically approved, due to the multiple...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Toxicol Rep
Main Authors: Tornatore, Laura, Capece, Daria, D'Andrea, Daniel, Begalli, Federica, Verzella, Daniela, Bennett, Jason, Acton, Gary, Campbell, Elizabeth A., Kelly, James, Tarbit, Michael, Adams, Nigel, Bannoo, Selina, Leonardi, Antonio, Sandomenico, Annamaria, Raimondo, Domenico, Ruvo, Menotti, Chambery, Angela, Oblak, Metod, Al-Obaidi, Magda J., Kaczmarski, Richard S., Gabriel, Ian, Oakervee, Heather E., Kaiser, Martin F., Wechalekar, Ashutosh, Benjamin, Reuben, Apperley, Jane F., Auner, Holger W., Franzoso, Guido
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6502747/
https://ncbi.nlm.nih.gov/pubmed/31080744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.toxrep.2019.04.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados